Urologic Oncology Articles

Tivozanib Recommended for EU Approval for RCC
The Committee for Medicinal Products for Human Use has adopted a positive opinion recommending marketing authorization of tivozanib for adult patients with advanced renal cell carcinoma.
Frontline Pembrolizumab Approval Leaves Questions for Later Lines in Bladder Cancer
Jorge Garcia, MD, discusses how the field of bladder cancer has transformed with the FDA approval of pembrolizumab, and how oncologists should choose between 5 checkpoint inhibitors now available for the second-line setting and beyond.
Feasibility Results Support Launching Full Phase III PART Trial in Prostate Cancer
Based on results of a feasibility study, researchers in the United Kingdom have decided to move forward with a full randomized controlled trial comparing partial prostate ablation with radical prostatectomy in patients with intermediate-risk prostate cancer.
Cross-Resistance to Docetaxel and Cabazitazel in CRPC Mediated by ABCB1 Gene
Results of an investigation indicate that resistance to docetaxel and cabazitaxel (Jevtana) in patients with castration-resistant prostate cancer is mediated by a common mechanism, overexpression of the ABCB1 gene.
Split-Dose Gemcitabine and Cisplatin Shows Good Responses in Neoadjuvant MIBC
Study results demonstrated that split-doses of gemcitabine and cisplatin as neoadjuvant chemotherapy for treating muscle-invasive bladder cancer has a good pathologic response with a high safety profile.
How Urology Clinics of North Texas Is Overcoming Payment Challenges
As manufacturers charge increasingly higher prices for new therapies and even well-established agents, payers have responded with pressure on practices to justify every cost, and Urology Clinics of North Texas, like many other independent practices, is caught in the middle.
Results from a blinded, independent data review confirmed previous results from the CABOSUN trial showing that treatment with cabozantinib (Cabometyx) extended progression-free survival compared with sunitinib (Sutent) for patients with previously untreated, intermediate- or poor-risk advanced renal cell carcinoma.
Recent Patterns Indicate PSA Testing Halt in Decline
A recent nationally representative study published in JAMA Internal Medicine found that previously reported declines in prostate-specific antigen testing have not continued in recent years, and that approximately one-third of men age 50 years or older still receive routine PSA tests.
Christophe Massard, MD, PhD, discusses the latest developments with durvalumab (Imfinzi) in urothelial carcinoma.
Petrylak Discusses Progress With Pembrolizumab in Urothelial Carcinoma
Daniel P. Petrylak, MD, discusses the KEYNOTE-045 results and the next steps with pembrolizumab (Keytruda) in urothelial carcinoma.
Publication Bottom Border
Border Publication